VocaVibe utilizes AI-based vocal biomarker analysis to passively monitor and diagnose Parkinson's disease, requiring no active effort from patients. The platform provides real-time insights into disease progression and treatment efficacy, enabling tailored care for patients and their healthcare providers.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's disease diagnosis and monitoring often rely on infrequent, subjective assessments, leading to delays in treatment adjustments and potentially impacting patient outcomes. Current methods may not provide continuous, objective data on disease progression and treatment efficacy.
Solution
VocaVibe offers an AI-powered platform that passively monitors Parkinson's disease progression through vocal biomarker analysis, eliminating the need for active patient participation. The technology analyzes subtle changes in speech patterns to provide real-time insights into disease severity, treatment response, and medication adherence. A clinician dashboard displays these objective metrics, enabling timely, data-driven adjustments to patient care plans. This approach facilitates proactive management of Parkinson's disease, potentially improving patient well-being and quality of life.
Target Audience
The primary target audience includes neurologists, healthcare providers specializing in Parkinson's disease, and patients seeking continuous, objective monitoring of their condition.
Features
- AI-driven analysis of vocal biomarkers for passive monitoring of Parkinson's disease
- Real-time tracking of disease progression, treatment efficacy, and medication adherence
- Clinician dashboard with alerts for proactive health management
- Objective, continuous data to support tailored care plans